Table 1.
A summary of the expression status and representative inhibitors of key regulators for cytokinesis as therapeutic targets of HCC.
| Protein name | Expression status in HCC | Representative inhibitors | Ref. |
|---|---|---|---|
| CDK1 | Up-regulated | JNJ-7706621, RO3306 | 50–57 |
| PRC1 | Up-regulated | N.A. | 58–61 |
| KIF4A | Up-regulated | N.A. | 25 , 62 , 63 |
| KIF4B | Up-regulated | N.A. | 62 , 64 |
| MKLP1 (KIF23) | Up-regulated | N.A. | 64–66 |
| MKLP2 (KIF20A) | Up-regulated | Paprotrain, BKS0349 | 67–71 |
| PLK1 | Up-regulated | DAP-81, BI 2536, BI 6727, Ro3280, TAK-960, NMS-P937, Poloxin, Poloxipan, Purpurogallin | 72–76 |
| PLK4 | LOH occurrs at the PLK4 locus in 50% HCC; protein level of PLK4 is significantly higher in HCC | CFI-400945, Centrinone/centrinone B, YLT-11 | 77–81 |
| AURKB | Up-regulated | VE-465, AZD1152-HQPA, AZD115229, MK0457, Deguelin | 82–90 |
| Survivin | Up-regulated | YM155, WM-127, Etoposide | 91–99 |
| ECT2 | Up-regulated | N.A. | 100–102 |
| RhoA | Up-regulated | L07, Y16, Zoledronic acid, CCG-203971, and CCG-1423 | 103–114 |
| MgcRacGAP | Up-regulated | MINC1 | 115–118 |